AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04605289
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be administered by means of a syringe with a bent, blunt-end needle. The needle will be carefully inserted into the periodontal pocket and the gel will be applied in the test sites in a gentle probing manner, attempting to fill the full extent of the pocket. The gel will be applied up to the gingival margin and the excess gel will be removed with sterile gauze.~Periodontal dressing will be applied after the delivery of the drug, and they will be also asked not to eat for thirty minutes.~After placement of the gel in situ, patients will be instructed to follow strict oral hygiene protocol and not chew hard or sticky foods at the gel placement sites for rest of the week.
Trial: NCT00506298
Drug: bezafibrate + diflunisal
RxNorm normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bezafibrate + diflunisal
Trial: NCT03178292
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Tablet daily for 5 days
Trial: NCT02990403
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00320060
Drug: Pyridorin (pyridoxamine dihydrochloride)
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00917826
Drug: Arginine Butyrate
RxNorm normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg/kg/day administered IV over 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)
Trial: NCT01950299
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 0.67 ml injections twice daily
Trial: NCT02291588
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: contains no active drug
Trial: NCT02941315
Drug: etiologic treatment,anti-myocardial remodeling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), participants were treated with drugs including etiologic treatment,anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.
Trial: NCT02941315
Drug: anti-myocardial remodeling
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant without companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.
Trial: NCT02941315
Drug: anti-myocardial remodeling,anti-acute heart failure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling and anti- acute failure according to guidelines.
Trial: NCT02941315
Drug: Etiological, anti-remodeling and symptom treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), in participants were companioned with acute heart failure, the participant should be treated with drugs including etiologic treatment,anti-myocardial remodeling and anti-acute heart failure according to guidelines for treatment of cardiomyopathy.
Trial: NCT02731378
Drug: Aggressive iron dextran supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron dextran 100 mg, BIW, through 90 minutes of IV infusion, for the first consecutive 5 weeks
Trial: NCT02731378
Drug: Sustained iron dextran supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron dextran 200 mg, Q3W, through 90 minutes of IV infusion and a maximum of 5 doses
Trial: NCT04512963
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A substance that has no therapeutic effect, used as a control in testing Progerinin
Trial: NCT02338713
Drug: Calcichew D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium 500 mg and vitamin D3 1000 IU chewable tablets
Trial: NCT02092454
Drug: Benzocaine
RxNorm normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical otic solution
Trial: NCT02092454
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical otic solution
Trial: NCT04574089
Drug: Experimental: Baofukang Suppository 7 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental: Baofukang Suppository 7 days
Trial: NCT04574089
Drug: Experimental: Baofukang Suppository 14 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental: Baofukang Suppository 14 days
Trial: NCT03280407
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Radio-chemotherapy with 50.4 Gy in 28 fractions to tumor and regional lymph nodes concomitantly with capecitabine 825 mg/m2 b.i.d
Trial: NCT03280407
Drug: FOLFOX regimen (oxaliplatin/leucovorin/5FU)
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six cycles: Oxaliplatin 85 mg/m2 day 1, leucovorin 400 mg/m2 day 1, 5FU 400 mg/m2 bolus day 1 and 5FU 2400 mg/ m2 over 46-48 hours day 1-3, repeated every two weeks.
Trial: NCT03280407
Drug: CAPOX (oxaliplatin/capecitabine)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Four cycles: Oxaliplatin 130 mg/m2 day 1 and capecitabine 1000 mg/m2 b.i.d. days 1-14, repeated every 3 weeks.
Trial: NCT02619617
Drug: SOM230
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study evaluated SOM230 vs Placebo
Trial: NCT02619617
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study evaluated SOM230 vs Placebo
Trial: NCT01967147
Drug: Propylene Glycol, 0.6% eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available eye drops used during Treatment Phase
Trial: NCT01967147
Drug: Preservative-free 0.9% Saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available solution used as Run-in (1 drop in each eye 4 times a day for 15 days) and during Treatment Phase
Trial: NCT01774877
Drug: Xinfeng capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinfeng capsule:Three each time, 3 times a day, Oral,for 3 months; placebo(for leflunomide):10mg each time, 1 time a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and NSAIDs that they were receiving prior to study entry
Trial: NCT02644395
Drug: Chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug
Trial: NCT02862587
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin：60mg/m2，Gemcitabine：1g/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
Trial: NCT03404856
Drug: ORL-1G - D-galactose
RxNorm normalized name: D(+)-Galactose
DrugBank: Galactose (DB11735)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ORL-1G - D-galactose
Trial: NCT03110328
Drug: MK3475
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-PD1 immunotherapy
Trial: NCT02603172
Drug: GSK3039294
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3039294 will be provided as white, opaque capsules. A single capsule or multiple capsules (20 mg to 200 mg), depending on the dosage required, will be taken orally with water.
Trial: NCT01936363
Drug: SAR245409 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching SAR245409 administered once daily in morning until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
Trial: NCT01936363
Drug: SAR245409
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR245409 administered as oral capsule at a dose of 70 milligram (mg) once daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
Trial: NCT00275171
Drug: recombinant human TSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg rhTSH administered intramuscularly
Trial: NCT01676493
Drug: Codeine
RxNorm normalized name: Codeine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01373697
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Apply the gel at the site of pain or injury, massaging gently to promote penetration of 8 in 8 hours for 5 days. Leave the gel on the premises at least 4 hours before removal
Trial: NCT02016443
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Placebo (Group P) will receive a placebo per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
Trial: NCT02762084
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03276598
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment for four weeks. Dose: 1 tablet per day.
Trial: NCT00053885
Drug: PTK787/ZK 222584
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00099086
Drug: GnRh analog
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A GnRH analog (goserelin acetate, leuprolide acetate) will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)~Bicalutamide will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)
Trial: NCT01043458
Drug: ABT-126
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-126 Low Dose \& ABT-126 High Dose
Trial: NCT01043458
Drug: Placebo for ABT-126
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo for Arms 1 \& 2
Trial: NCT01963702
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01139996
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo oral tablet and the overlay patch only and in 12 hours they will receive a second and final tablet
Trial: NCT01753882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agent + training vs Placebo + training
Trial: NCT01566604
Drug: NVA237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delivered via a single dose dry powder inhaler
Trial: NCT01566604
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delivered via a single dose dry powder inhaler
Trial: NCT00676403
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control (capsule), once a day, 1- 3 hours before bedtime for 6 weeks
Trial: NCT02634073
Drug: Sorbitol
RxNorm normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It is a clear, colorless, odourless solution. It will be available in 3 dosage levels viz;. 3.2 g (low dose), 10.2 g (medium dose) and 13.4 g (high dose) sorbitol total dose.
Trial: NCT02898454
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous
Trial: NCT00972959
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg, iv, at a 15 min infusion, Day 1 of every cycle for up to 8 cycles, and then every 28 days for the next 18 months
Trial: NCT00529711
Drug: Hypertonic lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution given parenterally as follows:~Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours.
Trial: NCT00529711
Drug: Ringer's lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution given parenterally as follows:~Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours.
Trial: NCT04302402
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar looking placebo
Trial: NCT02432339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a sugar pill - 500 mgs twice a day for 7 1/2 days - in the same capsule form as the MMF
Trial: NCT02718911
Drug: LY3022855
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT00467428
Drug: NS2359
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00467428
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05237726
Drug: Unfractionated heparin 5000 U q8 hours
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
Trial: NCT01820247
Drug: enteral nutrition
RxNorm normalized name: ENTERAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01820247
Drug: Tripterygium glycosides
RxNorm normalized name: anthraquinone glycoside
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03589807
Drug: AS03
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03 oil-in-water emulsion adjuvant.
Trial: NCT00672568
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution, single dose, injection
Trial: NCT03009864
Drug: Tangshen Prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The prescription contains granules of five Chinese herbal medicines, every bag weighs 4.87g, take it one bag each time, two times a day.
Trial: NCT03009864
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with placebo corresponding to each dose of Tangshen Prescription , every bag weighs 4.87g, take it one bag each time, two times a day.
Trial: NCT01906788
Drug: Artemether Lumefantrine
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02732808
Drug: Ovulation stimulation
RxNorm normalized name: Ovulation stimulants, synthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double stimulation in 2 phases:~Phase I: Clomiphene citrate (Ovumid®) 25 mg/day with co-treatment of Letrozole (Letrofem®) 2.5 mg/day are given from cycle day 3 onwards. Letrozole (Letrofem®) 2.5 mg/day are given from cycle day 3 onwards. human menopausal gonadotrophin (HMG) Menopur®150 IU every other day beginning on cycle day 6. triptorelin (Decapeptyl®) 100 μg follows by ibuprofen 600 mg.~Phase 2:A total of 225 IU HMG(Decapeptyl®) and letrozole (Letrofem®) 2.5 mg is administered daily .Daily administration of medroxyprogesterone acetate (Progestrone®)10 mg. . the final stage of oocyte maturation is induced again with triptorelin (Decapeptyl®)100 μg by injection.
Trial: NCT01435759
Drug: Antidepressant + Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, once daily for 8 weeks
Trial: NCT00757393
Drug: Vitamin D + Calcium + Exercise program + Humatrope
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in this arm will receive the same as those in arm 1 as well as Humatrope by subcutaneous infection 7 days a week at a dose of 0.05 mg.kg/day.
Trial: NCT01691690
Drug: Acetaminophen (paracetamol)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen IV (15 mg/kg).
Trial: NCT01691690
Drug: Normal Saline Flush
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo will be infused intraoperatively.
Trial: NCT01569126
Drug: LY110140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as capsules
Trial: NCT01569126
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as capsules in the placebo arm and to maintain the blind in the 20 mg LY110140 (MD) arm
Trial: NCT04062760
Drug: Standard diuretic therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients in this arm will be randomized to receiving oral furosemide in 2 daily divided doses at twice the intravenous dose administered during the past 24 hours. Unless serum potassium value is higher than 5 mmol/L, oral spironolactone or potassium canrenoate will be added; dose will be established based on serum creatinine value.
Trial: NCT00436072
Drug: ZD6474
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally on a daily basis
Trial: NCT01108926
Drug: Atripla®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will be administered Atripla® (tenofovir 245 mg plus emtricitabine 200 mg plus efavirenz 600 mg), one tablet orally once daily for 14 days
Trial: NCT02117453
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 20 mg/day
Trial: NCT02117453
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02392520
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous albumin administration, paracentesis of ascitic fluid, correction of electrolyte imbalance and intravascular volume
Trial: NCT00946023
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -6 and -5: 14.5 mg/kg IV daily; Days 3 and 4: 50 mg/kg IV daily
Trial: NCT00145769
Drug: Short Course Adjuvent Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post operative adjuvant chemotherapy: 5FU (425mg/m2) preceded by Folinic acid (20mg/m2) delivered over 5 days for 6 monthly cycles
Trial: NCT00145769
Drug: Long Course Adjuvant Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post operative adjuvant 5FU (425mg/m2) preceded by folinic acid (20mg/m2) delivered over 5 days for 4 monthly cycles
Trial: NCT00024141
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02710708
Drug: EE20/DRSP (YAZ, BAY86-5300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YAZ (DRSP 3 mg/EE 20 µg), oral route, 6 cycles of 28 days per cycle, each cycle comprising 24 days of active tablets followed by 4 days of placebo tablets
Trial: NCT02324010
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive drug (Placebo)
Trial: NCT00667056
Drug: placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical
Trial: NCT04410510
Drug: P2Et (Caesalpinia spinosa extract)
RxNorm normalized name: Caesalpinia spinosa whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P2Et active extract capsule equivalent to 250mg of P2Et every 12 hours for 14 days + Standard Care
Trial: NCT00432861
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT00697021
Drug: Aspirin 100mg and Plavix 75mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Responders to standard dual antiplatelet therapy as observed by TEG analysis will continue standard doses of Aspirin and Plavix
Trial: NCT02607670
Drug: TAT4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02607670
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01052246
Drug: Fixed combination of clindamycin 1% + benzoyl peroxide 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical monotherapy with a fixed combination of 1% clindamycin and 5% benzoyl peroxide hydrating gel (Duac® Akne Gel, Stiefel Laboratorium GmbH, Offenbach, Germany). In order to provide standardized condition within the sample, the gel was applied on the whole face regardless of the lesion location. The gel was applied once per day in the evening throughout the observation period and left in place overnight.
Trial: NCT00288262
Drug: melatonin 0.5 mg
RxNorm normalized name: melatonin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03081247
Drug: BGF 320/14.4/9.6 µg MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler (BGF MDI)
Trial: NCT00057408
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT03665779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 pregnant females, induction will be done by placebo (pyridoxine) administered in the posterior vaginal fornix.repeated every 4 hours maximum 4 times
Trial: NCT04506645
Drug: REGN5381
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose REGN5381 administered via IV infusion
Trial: NCT03081247
Drug: BFF 320/9.6 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide and Formoterol Fumarate metered dose inhaler (BFF MDI)
Trial: NCT00384774
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as intravenous infusion
Trial: NCT02550743
Drug: BYL719
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02550743
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02361034
Drug: GRC 27864
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02361034
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no